摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-methoxy-2-phenyloxazole | 40527-16-0

中文名称
——
中文别名
——
英文名称
5-methoxy-2-phenyloxazole
英文别名
5-phenyl-5-methoxyoxazole;5-methoxy-2-phenyl-oxazole;5-Methoxy-2-phenyl-oxazol;5-Methoxy-2-phenyloxazol;5-methoxy-2-phenyl-1,3-oxazole
5-methoxy-2-phenyloxazole化学式
CAS
40527-16-0
化学式
C10H9NO2
mdl
——
分子量
175.187
InChiKey
SAPZPJYIYCXFEA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    306.47°C (rough estimate)
  • 密度:
    1.1999 (rough estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    35.3
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    5-methoxy-2-phenyloxazole三氟化硼乙醚 作用下, 以 乙腈 为溶剂, 反应 12.0h, 生成
    参考文献:
    名称:
    Photocycloadditions of substituted oxazoles with isoquinoline-1,3,4-trione—chemo-, regio-, diastereoselectivities and transformation of the photocycloadducts
    摘要:
    不同取代基的异喹啉-1,3,4-三酮和噁唑的光反应发现具有不同的化学选择性、区域选择性和非对映选择性。噁唑环C5处的取代基对光反应的化学选择性以及光环加成产物的转化有很大影响。2-甲基-5-甲氧基噁唑与异喹啉-1,3,4-三酮反应迅速,产生具有高区域选择性和非对映选择性的螺氧烷。2-苯基-5-甲氧基噁唑与异喹啉-1,3,4-三酮的反应中的非对映选择性与噁唑环4位的取代基相关。用5-甲基或5-苯基替换5-甲氧基过程显著降低了噁唑的反应活性,并改变了与异喹啉-1,3,4-三酮的光环加成反应中的非对映选择性。酸介导的光环加成产物螺氧烷的转化在不同反应条件下发现可以生成不同类型的产物,包括β-羟基-α-氨基碳基化合物和螺异喹啉噁唑啉。螺氧烷上的取代基以及反应中使用的酸的类型和量在确定产物的类型和非对映选择性方面起着重要作用。
    DOI:
    10.1039/c3ob40645h
  • 作为产物:
    描述:
    N-苯甲酰基甘氨酸甲酯三乙胺三苯基膦 作用下, 以98%的产率得到5-methoxy-2-phenyloxazole
    参考文献:
    名称:
    MAX BINDERS AS MYC MODULATORS AND USES THEREOF
    摘要:
    本公开提供了Formula (I′)、Formula (I)、Formula (II)、Formula (II-A)、Formula (III)和Formula (IV)的化合物。本文描述的化合物是MAX结合蛋白和/或Myc、Mad或Mxi1的调节剂(例如,Myc、Mad或Mxi1的抑制剂),可能在治疗与Myc相关的疾病的患者中有用,例如增殖性疾病(例如癌症)。本公开还提供了包括上述化合物的药物组合物和试剂盒,以及使用这些化合物、组合物和试剂盒的方法和用途。
    公开号:
    US20170233405A1
点击查看最新优质反应信息

文献信息

  • Addition of Azomethine Ylides to Aldehydes: Mechanistic Dichotomy of Differentially Substituted α-Imino Esters
    作者:Brinton Seashore-Ludlow、Staffan Torssell、Peter Somfai
    DOI:10.1002/ejoc.201000377
    日期:——
    of azomethine ylides and aldehydes is explored, as hydrolysis of the resulting oxazolidine product gives facile access to valuable syn-β-aryl-β-hydroxy-α-amino esters. The use of using benzaldehyde-derived imines as the ylide precursor results in 1,3-dipolar cycloaddition with high conversions but low diastereoselectivity. In contrast, the employment of benzophenone-derived imines as the ylide precursor
    探索了偶氮甲碱叶立德和醛的正式 1,3-偶极环加成反应,因为所得恶唑烷产物的解可以轻松获得有价值的顺-β-芳基-β-羟基-α-基酯。使用苯甲醛衍生的亚胺作为叶立德前体导致 1,3-偶极环加成反应具有高转化率但非对映选择性低。相比之下,使用二苯甲酮衍生的亚胺作为叶立德前体会导致羟醛反应,从而产生具有高非对映选择性的中间体恶唑烷,并且需要弱酸催化剂来实现更高的转化率。
  • SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME
    申请人:Board of Regents, The University of Texas System
    公开号:US20130184317A1
    公开(公告)日:2013-07-18
    Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.
    本文描述了结合Pleckstrin同源结构域的化合物、包括此类化合物的制药组合物以及使用它们的方法。
  • Max binders as MYC modulators and uses thereof
    申请人:Massachusetts Institute of Technology
    公开号:US10106555B2
    公开(公告)日:2018-10-23
    The present disclosure provides compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.
    本公开提供了式(I′)、式(I)、式(II)、式(II-A)、式(III)和式(IV)化合物。本文所述化合物是MAX粘合剂和/或Myc、MAd或Mxi1的调节剂(如Myc、MAd或Mxi1的抑制剂),可用于治疗与Myc相关的疾病,如增殖性疾病(如癌症)。本公开还提供了包括本文所述化合物的药物组合物和试剂盒,以及化合物、组合物和试剂盒的使用方法和用途。
  • Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
    申请人:Murphy Patrick Bryan
    公开号:US20050198745A1
    公开(公告)日:2005-09-15
    Five-membered heteroaromatic keratin dyeing compounds with one, two, or three heteroatoms. This invention further relates to a composition for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and one or more 5-membered heteroaromatic keratin dyeing compounds with one, tow, or three heteroatoms. This invention further relates to a method for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period sufficient to develop the desired coloration.
    具有一个、两个或三个杂原子的五元杂芳香族角蛋白染色化合物。本发明还涉及一种用于角蛋白纤维氧化染色的组合物,该组合物包含一种适于染色的介质和一种或多种具有一个、两个或三个杂原子的五元杂芳香族角蛋白染色化合物。本发明还涉及一种对角蛋白纤维进行氧化染色的方法,包括在有氧化剂存在的情况下,在足以形成所需着色的时间内使用这种组合物。
  • Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
    作者:Nicholas B. Struntz、Andrew Chen、Anja Deutzmann、Robert M. Wilson、Eric Stefan、Helen L. Evans、Maricela A. Ramirez、Tong Liang、Francisco Caballero、Mattheus H.E. Wildschut、Dylan V. Neel、David B. Freeman、Marius S. Pop、Marie McConkey、Sandrine Muller、Brice H. Curtin、Hanna Tseng、Kristen R. Frombach、Vincent L. Butty、Stuart S. Levine、Clementine Feau、Sarah Elmiligy、Jiyoung A. Hong、Timothy A. Lewis、Amedeo Vetere、Paul A. Clemons、Scott E. Malstrom、Benjamin L. Ebert、Charles Y. Lin、Dean W. Felsher、Angela N. Koehler
    DOI:10.1016/j.chembiol.2019.02.009
    日期:2019.5
    The transcription factor Max is a basic-helix-loop-helix leucine zipper (bHLHLZ) protein that forms homodimers or interacts with other bHLHLZ proteins, including Myc and Mxd proteins. Among this dynamic network of interactions, the Myc/Max heterodimer has crucial roles in regulating normal cellular processes, but its transcriptional activity is deregulated in a majority of human cancers. Despite this significance, the arsenal of high-quality chemical probes to interrogate these proteins remains limited. We used small molecule microarrays to identify compounds that bind Max in a mechanistically unbiased manner. We discovered the asymmetric polycyclic lactam, KI-MS2-008, which stabilizes the Max homodimer while reducing Myc protein and Myc-regulated transcript levels. KI-MS2-008 also decreases viable cancer cell growth in a Myc-dependent manner and suppresses tumor growth in vivo. This approach demonstrates the feasibility of modulating Max with small molecules and supports altering Max dimerization as an alternative approach to targeting Myc.
查看更多